BeiGene files for IPO on NASDAQ

BeiGene Ltd. (Beijing, China) filed to raise up to $100 million in an IPO of ADSs on NASDAQ underwritten by Goldman Sachs; Morgan Stanley; Cowen; and Baird.

The company is running a Phase I study of BGB-3111, an oral Bruton's tyrosine kinase (Btk) inhibitor, to treat select lymphoid malignancies. It is also conducting Phase I studies, including one that began this month in China, of BGB-283, a small molecule, second-generation BRAF inhibitor to treat solid tumors. ...